Advanced Drug Resistance SNP Analysis And Monitoring Of Liver Physiological Changes During Hepatitis B Virus Infection | 4872
Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Nucleoside analogue therapy allows the safe and long-term suppression of HBV. Lamivudine is a common drug for the
treatment of chronic HBV patients. Resistant hepatitis B virus occurs as natural genome variables in YMDD motif of
Lamivudine-treated and untreated chronic hepatitis B patients. Resistance detection is mainly accomplished by conventional
lab methods and commercial kits. In this study we aimed to establish a Next Generation Sequencing?based method to detect
Lamivudine-resistance by designing probes for a specific region of HBV genome. Meanwhile we monitored the physiological
changes of liver before and during the treatment. Genomic DNA from serum samples of 92 patients with chronic hepatitis
B virus infection was extracted. All patients were tested for liver enzymes, HbsAg, HbcAg, HbeAg, anti-HBs, anti-Hbe, anti-
HBc, Bilirubin, Albumin and liver biopsy. NGS was accomplished using MINI-20 Sequencer by use of a mixture of reversible
terminated dNTPs and Biotinylated DNA sense and antisense probes. In mix population status some mutants are not detected
using conventional methods such as RFLP, nested-PCR or even common sequencing. Thus in resistant patient Lamivudine
treatment is led to disease recurrence. Based on our findings Next Generation Sequencing could be more efficient, less time
consuming and more sensitive for detection of mixed population of all YMDD motif mutants even rare single nucleotide
mutation. It is also more accurate, faster, and more low-cost for patients.
Samira Salehnejad has completed her M.Sc. in Animal Physiology from Shahrekord University, IRAN. She co-founded PooyaGene Biotech
Company, 2008 in IRAN as a research-driven and knowledge-based company, focusing on molecular diagnostic, stem cell and biopharmaceuticals
research and manufacturing, with a branch in INDIA. She is already working as Senior Manager of PooyaGene Biotech Co.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals